CORDIS
EU research results

CORDIS

English EN
Epilepsy Pharmacogenomics: delivering biomarkers for clinical use

Epilepsy Pharmacogenomics: delivering biomarkers for clinical use

Objective

The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).
The need for improved treatments in epilepsy is undoubted. Epilepsy is affects 50,000,000 people of all ages worldwide. Epilepsy is serious, increasing morbidity across all aspects of life, including a high risk of premature mortality. Over 20 antiepileptic drugs (AEDs) are licenced for its treatment. Seizures can be effectively controlled by AEDs in ~70% of people. Control of seizures leads to risk reduction for most of consequences of epilepsy, improves quality of life, permits social re-integration and leads to direct economic benefits. However, in 30% of patients, currently-available AEDs do not control seizures – recurrent seizures threaten life and impair its quality in these patients, and account for much of the €15.5 billion annual cost of epilepsy in the EU alone; there is currently no way to predict which patients will not respond to any or all AEDs; even in the 70% who do respond, only 47% respond to the first AED – whilst the correct drug is being sought, risks from seizures continue – we need to be able to predict the right drug for an individual from the outset; unrelated to responder status, AEDs can cause serious ADRs – a biomarker exists for only one ADR; there is a clear need for novel means of discovery of new AEDs – existing AEDs are anti-seizure drugs, not disease-modifying drugs.
We will use genome-wide analyses, including next-generation sequencing, in large, well-phenotyped patient cohorts to identify genome-based biomarkers, to improve use of current AEDs and identify new therapy targets.
SMEs, which are central to this project, will be able to take the data forward for development of clinical tests; data will also be invaluable for industry seeking to develop new treatments.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY COLLEGE LONDON

Address

Gower Street
Wc1e 6bt London

United Kingdom

Activity type

Other

EU Contribution

€ 1 066 961

Administrative Contact

Greta Borg-Carbott (Ms.)

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 283 761

ISTITUTO GIANNINA GASLINI

Italy

EU Contribution

€ 252 864

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 411 802

Stichting Epilepsie Instellingen Nederland

Netherlands

EU Contribution

€ 89 498

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 169 542

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland

EU Contribution

€ 323 536

BELFAST HEALTH AND SOCIAL CARE TRUST

United Kingdom

EU Contribution

€ 100 752

ISLENSK ERFDAGREINING EHF

Iceland

EU Contribution

€ 2 146 572

UNIVERSITE DU LUXEMBOURG

Luxembourg

EU Contribution

€ 298 752

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 100 425

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 212 901

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 101 304

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 106 444

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 332 882

Project information

Grant agreement ID: 279062

Status

Closed project

  • Start date

    1 November 2011

  • End date

    31 October 2015

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 838 258,80

  • EU contribution

    € 5 997 996

Coordinated by:

UNIVERSITY COLLEGE LONDON

United Kingdom